Last reviewed · How we verify
Cabazitaxel in mCRPC Patients With AR-V7 Positive Circulating Tumor Cells (CTCs) (CABA-V7)
After failure on docetaxel, which has been the standard first line therapy for patients with metastatic castration-resistant prostate cancer (mCRPC), several treatment options are currently available. In retrospective studies, resistance has been described to two of the treatment options, enzalutamide and abiraterone, when a splice variant of the Androgen Receptor (AR-V7) is present on circulating tumor cells (CTCs). The investigators hypothesize that patients with AR-V7 positive CTCs do have a meaningful response to cabazitaxel.
Details
| Lead sponsor | Erasmus Medical Center |
|---|---|
| Phase | PHASE2 |
| Status | UNKNOWN |
| Enrolment | 140 |
| Start date | Tue Feb 21 2017 00:00:00 GMT+0000 (Coordinated Universal Time) |
| Completion | Fri Aug 19 2022 00:00:00 GMT+0000 (Coordinated Universal Time) |
Conditions
- Circulating Tumor Cell
- Metastatic Prostate Cancer
Interventions
- Cabazitaxel
- Antihistamine
- Corticosteroid
- H2 antagonist
- Antiemetic
Countries
Netherlands